Published in Mol Pharmacol on January 26, 2010
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res (2014) 1.25
Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) (2010) 1.19
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun (2015) 1.01
Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol (2012) 0.95
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Ethanol extract of paeonia suffruticosa Andrews (PSE) induced AGS human gastric cancer cell apoptosis via fas-dependent apoptosis and MDM2-p53 pathways. J Biomed Sci (2012) 0.88
Cancer and diet: How are they related? Free Radic Res (2011) 0.81
Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway. Biochem Res Int (2013) 0.81
Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway. Exp Ther Med (2013) 0.80
Molecular Mechanism for Cellular Response to β-Escin and Its Therapeutic Implications. PLoS One (2016) 0.77
Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. BMC Immunol (2010) 0.77
Ac-SDKP suppresses TNF-α-induced ICAM-1 expression in endothelial cells via inhibition of IκB kinase and NF-κB activation. Am J Physiol Heart Circ Physiol (2016) 0.76
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
Nuclear factor-kappaB: the enemy within. Cancer Cell (2004) 6.86
IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene (2006) 3.84
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene (2006) 1.68
Assay for redox-sensitive transcription factor. Methods Enzymol (2000) 1.65
Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res (2001) 1.19
Effect of aescine on hypoxia-induced activation of human endothelial cells. Eur J Pharmacol (1996) 0.97
Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg (2005) 0.93
Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. Planta Med (2007) 0.91
Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther (2006) 0.87
Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med (2002) 0.87
Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull (1997) 0.86
Anti-obesity effects of escins extracted from the seeds of Aesculus turbinata BLUME (Hippocastanaceae). Chem Pharm Bull (Tokyo) (2008) 0.84
Effects of beta-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats. J Zhejiang Univ Sci B (2005) 0.84
[New findings on the efficacy and mode of action of the horse chestnut saponin escin]. Arzneimittelforschung (1976) 0.83
Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial. Clin Ther (2004) 0.83
Identification of novel saponins from edible seeds of Japanese horse chestnut (Aesculus turbinata Blume) after treatment with wooden ashes and their nutraceutical activity. J Pharm Biomed Anal (2006) 0.83
Mode of action of escins Ia and IIa and E,Z-senegin II on glucose absorption in gastrointestinal tract. Bioorg Med Chem (1998) 0.82
Effects of beta-aescin on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin (2004) 0.82
[Clinical effect of escin on patients with cutaneous pruritus caused by blood stasis and wind-dryness]. Zhong Xi Yi Jie He Xue Bao (2004) 0.79
Gastroprotections of escins Ia, Ib, IIa, and IIb on ethanol-induced gastric mucosal lesions in rats. Eur J Pharmacol (1999) 0.79
Anti-HIV-1 protease triterpenoid saponins from the seeds of Aesculus chinensis. J Nat Prod (1999) 0.79
Influence of alpha-escin on the femoral bone strength in ovariectomized rats. Pol J Pharmacol (2000) 0.78
Bioactive saponins and glycosides. III. Horse chestnut. (1): The structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L. Chem Pharm Bull (Tokyo) (1996) 0.78
Antisecretory and gastroprotective effects of aescine in rats. Gen Pharmacol (1994) 0.78
Influence of alpha-escin on skeletal changes in ovariectomized rats. Acta Pol Pharm (2000) 0.78
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 2.98
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology (2002) 2.38
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20
Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10
Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol (2012) 2.09
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med (2007) 2.03
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer (2007) 1.86
The molecular inflammatory process in aging. Antioxid Redox Signal (2006) 1.86
Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc (2011) 1.83
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79
CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer (2009) 1.79
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol (2008) 1.77
Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72
Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72
Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem (2004) 1.66
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63
Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 1.63
Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep (2011) 1.62
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer (2010) 1.62